BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Jan. 9, 2018
View Archived Issues
Mallinckrodt completes rolling submission of NDA for stannsoporfin
Read More
BioCryst Pharmaceuticals begins IND-enabling studies of two lead candidates
Read More
Jiangsu Chia Tai Tianqing Pharmaceutical Group and others patent JAK2 inhibitors
Read More
KalVista Pharmaceuticals initiates two clinical studies of plasma kallikrein inhibitors
Read More
F1 Oncology announces milestone in development of CCT301-38 AXL and CCT301-59 ROR2
Read More
Galapagos reports topline results from phase Ib study of GLPG-1972 in osteoarthritis
Read More
Ultragenyx reports first cohort data from phase I/II study of DTX-301 to treat OTC deficiency
Read More
Sperm cell-driven approach for targeted drug delivery in gynecological malignancies
Read More
Exelixis and StemSynergy enter into exclusive licensing agreement
Read More
Alcyone enters collaboration to improve intrathecal delivery of drugs for rare CNS disorders
Read More
FDA accepts Merck & Co.'s NDAs for doravirine
Read More
Cas9-Tmc1-mut3 RNP genome editing agent shows promise in model of autosomal dominant hearing loss
Read More
Virus-like particle vaccine targeting xCT active in breast cancer models
Read More
Novel TrpC5 ion channel inhibitor shows promise in models of progressive kidney disease
Read More
Cleveland Clinic Foundation creates novel anti-CD6 antibodies
Read More
Denali Therapeutics identifies new LRRK2 inhibitors
Read More
Preliminary results from part 1 of phase II trial of ACE-083 in patients with FSHD
Read More
New PTP-2C inhibitors synthesized at Novartis
Read More
bluebird bio describes novel TPP1 gene therapy
Read More
AbbVie's upadacitinib awarded FDA breakthrough therapy designation for atopic dermatitis
Read More
China FDA accepts IND for Ascentage's IAP inhibitor
Read More
BeiGene licenses rights to Mirati's sitravatinib
Read More
Ablynx believes Novo Nordisk's proposal to acquire Ablynx undervalues company
Read More
ProQR collaborates with Galapagos on fibrosis programs
Read More
Dynavax makes Heplisav-B available in U.S.
Read More
Grant supports Sabin Vaccine Institute's focus on next-generation influenza vaccines
Read More
First efficacy endpoint met in phase II trial of bemcentinib in NSCLC
Read More
Regeneron and Sanofi to expand investment in cemiplimab and dupilumab programs
Read More
Pivotal study of eptinezumab for migraine prevention meets key endpoints
Read More
FDA accepts Ionis' inotersen NDA for priority review
Read More
REGENXBIO and AveXis amend licensing agreement for spinal muscular atrophy products
Read More
New phase II clinical data presented for radioiodinated tositumomab in NHL
Read More